MAPT and Alzheimer disease: Though increase in CSF total-tau is used routinely in clinic for AD diagnosis, we are fully aware that phospho-tau measurements (e.g. p-Tau 181 or p-Tau 217) are more sensitive to detect AD pathology [31], they were not possible to achieve in the triplex panel available.